JD5037

Uses your system voice; voice and rate in settings.

Q6107933Snapshot

≈ 3 min read

Names in other languages

  • EnglishJD5037

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

JD5037 is an antiobesity drug candidate which acts as a peripherally-restricted cannabinoid inverse agonist at CB 1 receptors. It is very selective for the CB 1 subtype, with a Ki of 0.35nM, >700-fold higher affinity than it has for CB 2 receptors. In animal studies, JD5037 does not readily cross the blood brain barrier and thus is not expected to produce the psychiatric side effects in humans which led to the withdrawal of rimonabant from the market.

Evidence and sources

Its antiobesity effects are believed to be mediated by blockade of peripheral CB 1 receptors, resulting in decreased leptin expression and secretion and increased leptin clearance by the kidneys. In obese mice given the drug, the resulting resensitization to leptin levels produced decreased food intake, weight loss, and normalized responses to glucose and insulin. In a study of mice, JD5037 reduced the consumption of alcohol.

JD5037 is covered in the following US Patents issued to Jenrin Discovery: 8,088,809 (1/3/12) ), 7,666,889 (2/23/10), 7,482,470 (1/27/09). The synthesis of JD-5037 and related analogs along with structure activity relationships has been reported. A review on the approaches and compound types being pursued as peripherally restricted CB1 receptor blockers, including JD5037, has been published.

JD5037 is an antiobesity drug candidate which acts as a peripherally-restricted cannabinoid inverse agonist at CB 1 receptors. It is very selective for the CB 1 subtype, with a Ki of 0.35nM, >700-fold higher affinity than it has for CB 2 receptors. In animal studies, JD5037 does not readily cross the blood brain barrier and thus is not expected to produce the psychiatric side effects in humans which led to the withdrawal of rimonabant from the market.

Its antiobesity effects are believed to be mediated by blockade of peripheral CB 1 receptors, resulting in decreased leptin expression and secretion and increased leptin clearance by the kidneys. In obese mice given the drug, the resulting resensitization to leptin levels produced decreased food intake, weight loss, and normalized responses to glucose and insulin. In a study of mice, JD5037 reduced the consumption of alcohol.

JD5037 is covered in the following US Patents issued to Jenrin Discovery: 8,088,809 (1/3/12) ), 7,666,889 (2/23/10), 7,482,470 (1/27/09). The synthesis of JD-5037 and related analogs along with structure activity relationships has been reported. A review on the approaches and compound types being pursued as peripherally restricted CB1 receptor blockers, including JD5037, has been published.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330316207 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.